UY39118A - ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19) - Google Patents

ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19)

Info

Publication number
UY39118A
UY39118A UY0001039118A UY39118A UY39118A UY 39118 A UY39118 A UY 39118A UY 0001039118 A UY0001039118 A UY 0001039118A UY 39118 A UY39118 A UY 39118A UY 39118 A UY39118 A UY 39118A
Authority
UY
Uruguay
Prior art keywords
sars2
cov
antibodies
covid
antibodies against
Prior art date
Application number
UY0001039118A
Other languages
English (en)
Inventor
Gerardus Grosveld Franklin
Dubravka Drabek
van Haperen Rien
Jan Bosch Berend
Juliette Fedry
L Hurdiss Daniel
Thijs Kuiken
Leonardus Haagmans Bartholomeus
Hubertus Gerardus Rockx Barry
Original Assignee
Univ Utrecht Holding Bv
Harbour Antibodies Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utrecht Holding Bv, Harbour Antibodies Bv filed Critical Univ Utrecht Holding Bv
Publication of UY39118A publication Critical patent/UY39118A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anticuerpos y fragmentos de unión al antígeno de los mismos que reconocen proteínas de la espícula de SARS-Cov-2 (SARS2-S). En algunas formas de realización, los anticuerpos se unen a SARS2-S con una gran afinidad y/o inhiben una infección por SARS-Cov-2 en células humanas. En algunas formas de realización, los anticuerpos proveen un medio para prevenir, tratar o mejorar una infección por SARS2. En algunas formas de realización, los anticuerpos se usan en ensayos de diagnóstico (por ejemplo, ensayos de serodiagnóstico para SARS2).
UY0001039118A 2020-03-12 2021-03-05 ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19) UY39118A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2003632.3A GB202003632D0 (en) 2020-03-12 2020-03-12 SARS-Cov-2 (SARS2, COVID-19) antibodies
GBGB2004340.2A GB202004340D0 (en) 2020-03-12 2020-03-25 SARS-Cov-2 (SARS2, COVID-19) Antibodies
GBGB2013024.1A GB202013024D0 (en) 2020-03-12 2020-08-20 Sars-Cov-2 (SARS2, COVID-19) antobodies
GBGB2015240.1A GB202015240D0 (en) 2020-03-12 2020-09-25 SARS-Cov-2 (SARS2, COVID-19) Antibodies
GBGB2101720.7A GB202101720D0 (en) 2020-03-12 2021-02-08 Sars-cov-2 (sars2, covid-19) antibodies

Publications (1)

Publication Number Publication Date
UY39118A true UY39118A (es) 2021-10-29

Family

ID=70453696

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039118A UY39118A (es) 2020-03-12 2021-03-05 ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19)

Country Status (6)

Country Link
US (2) US20210340225A1 (es)
AR (1) AR121522A1 (es)
GB (5) GB202003632D0 (es)
TW (1) TW202200612A (es)
UY (1) UY39118A (es)
WO (2) WO2021180602A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113766928A (zh) 2020-04-02 2021-12-07 瑞泽恩制药公司 抗sars-cov-2纤突糖蛋白抗体和抗原结合片段
CN117362422A (zh) * 2020-04-30 2024-01-09 养生堂有限公司 针对SARS-CoV-2的抗体及其用途
IL298035A (en) 2020-05-08 2023-01-01 Academia Sinica Chimeric influenza vaccines
CN116964086A (zh) * 2020-05-18 2023-10-27 艾佩斯瑞生物制药公司 抗SARS-CoV-2抗体和其用途
CN112979791B (zh) * 2020-05-27 2021-12-10 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒的抗体
CN112979790B (zh) * 2020-05-27 2022-02-11 江苏省疾病预防控制中心(江苏省公共卫生研究院) 抗体及在检测新型冠状病毒中的用途
CN112898415B (zh) * 2020-05-27 2021-12-10 江苏省疾病预防控制中心(江苏省公共卫生研究院) 一种检测新型冠状病毒的抗体及检测试剂盒
CN111518203B (zh) * 2020-05-27 2021-10-19 江苏省疾病预防控制中心(江苏省公共卫生研究院) 用于新型冠状病毒检测的试剂盒
CN112898416B (zh) * 2020-05-27 2022-02-11 江苏省疾病预防控制中心(江苏省公共卫生研究院) 新型冠状病毒np蛋白的结合蛋白及其应用
CN112979793B (zh) * 2020-05-27 2022-02-11 江苏省疾病预防控制中心(江苏省公共卫生研究院) 检测新型冠状病毒的抗体
CN111518202B (zh) * 2020-05-27 2021-10-19 江苏省疾病预防控制中心(江苏省公共卫生研究院) 新型冠状病毒抗体和新型冠状病毒抗体的elisa检测试剂盒
CN113831409B (zh) * 2020-06-08 2023-04-25 中国科学院深圳先进技术研究院 一种抗sar-cov-2抗体或其抗原结合片段及其应用
CN113896788B (zh) * 2020-06-22 2023-05-23 中国科学院深圳先进技术研究院 抗sar-cov-2（covid-19）全人源单克隆抗体及其制法与应用
CN113480644B (zh) * 2020-08-10 2022-09-16 南开大学 一种抗冠状病毒的抗体及其应用
CN117003862A (zh) * 2020-08-19 2023-11-07 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
CN111909260B (zh) * 2020-08-19 2022-06-21 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
CN111909262B (zh) * 2020-08-19 2022-10-04 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
WO2022101839A1 (en) * 2020-11-12 2022-05-19 Cadila Healthcare Limited Anti-sars-cov-2 monoclonal antibodies and cocktail thereof
US11693011B2 (en) * 2020-12-14 2023-07-04 Inbios International, Inc. Neutralizing antibody immunoassays
US20230002478A1 (en) * 2021-06-22 2023-01-05 Twist Bioscience Corporation Methods and compositions relating to covid antibody epitopes
WO2023048656A2 (en) * 2021-09-24 2023-03-30 Chulalongkorn University Human monoclonal antibodies against the receptor-binding domain of sars-cov-2 spike protein
TW202334429A (zh) * 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
AU2022361501A1 (en) * 2021-10-07 2024-05-02 Seqirus Pty Ltd Anti-sars-cov-2 antibodies and uses thereof i
WO2023184280A1 (zh) * 2022-03-30 2023-10-05 上海科技大学 一种抗新冠纳米抗体及其应用
WO2024007013A2 (en) * 2022-06-30 2024-01-04 Modex Therapeutics, Inc. Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988001513A1 (en) 1986-08-28 1988-03-10 Teijin Limited Cytocidal antibody complex and process for its preparation
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
PT2311874T (pt) 2004-07-22 2017-08-25 Univ Erasmus Med Ct Rotterdam Moléculas de ligação
EP1991580A2 (en) 2006-01-25 2008-11-19 Erasmus University Medical Center Rotterdam Generation of heavy-chain only antibodies in transgenic animals
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP2242768A4 (en) * 2008-01-17 2012-03-14 Humabs Llc CROSS-NEUTRALIZATION OF HUMAN MONOCLONAL ANTIBODIES AGAINST SARS-COV AND METHODS FOR THEIR APPLICATION
MX2011007660A (es) 2008-12-18 2011-08-17 Kingdon Craig R Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos.
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP4356927A2 (en) * 2012-10-12 2024-04-24 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
ES2829376T3 (es) 2013-03-14 2021-05-31 Univ Erasmus Med Ct Rotterdam Mamífero no humano transgénico para la producción de anticuerpos
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
WO2021180602A1 (en) 2021-09-16
WO2021180604A1 (en) 2021-09-16
GB202004340D0 (en) 2020-05-06
GB202015240D0 (en) 2020-11-11
GB202003632D0 (en) 2020-04-29
GB202101720D0 (en) 2021-03-24
TW202200612A (zh) 2022-01-01
US20210340225A1 (en) 2021-11-04
GB202013024D0 (en) 2020-10-07
AR121522A1 (es) 2022-06-08
US20220017606A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
AR121522A1 (es) ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19)
CO2022013525A2 (es) Anticuerpos contra sars-cov-2 y métodos para usarlos
CL2023000705A1 (es) Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
CL2020003422A1 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
CU20170169A7 (es) Anticuerpos de factor xi
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
BR112014021081A2 (pt) anticorpos para a metaloproteinase da matriz 9
CL2019003520A1 (es) Anticuerpos que se unen específicamente a pd-1 y procedimientos de uso.
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
AR083293A1 (es) Agentes de union a cd33
CR11783A (es) Molecula de union al antigeno capaz de unirse repetidamente a dos o mas moleculas de antigeno
CO7061040A2 (es) Anticuerpos contra la metaloproteinasa de la matriz 9
BR112022010179A2 (pt) Anticorpos anti-vírus da febre amarela, e métodos de sua geração e uso
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
DOP2021000145A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
BR112021012667A2 (pt) Proteínas de ligação anti-pd-1 e métodos de uso destas
CO2022002001A2 (es) Usos terapéuticos de anticuerpos anti-variable delta 1 de tcr
AR122111A1 (es) ANTICUERPOS CONTRA EL SARS-CoV-2 Y MÉTODOS DE SELECCIÓN Y USO DE LOS MISMOS
AR115257A1 (es) Anticuerpos de fijación a bcma y sus usos
DOP2023000039A (es) Moléculas de unión a antígeno multi-específicas contra el vih y métodos de uso
CL2022000052A1 (es) Anticuerpos de pre–direccionamiento y metodos de uso
UY38289A (es) Proteína de unión al antígeno anti-steap1
CL2023003084A1 (es) Anticuerpos antiestafilococo y usos de estos